Contineum Therapeutics, Inc.

What they do

Contineum discovers and develops selective small molecule drug candidates targeting biological pathways in neuroscience, inflammation and immunology (NI&I). Its wholly-owned lead asset, PIPE-791, is an LPA1R inhibitor in a Phase 2 trial for idiopathic pulmonary fibrosis and was tested in a Phase 1b chronic pain trial. Its second candidate, PIPE-307, an M1R inhibitor, is licensed to Johnson & Johnson, which is running a Phase 2 trial in major depressive disorder. The company has no approved products; its 2023 revenue of $50.0M relates to a collaboration and no revenue has been reported since.

Revenue drivers

• Collaboration revenue (historical) — The company reported $50.0M of revenue in 2023, tied to the February 2023 J&J license agreement for PIPE-307, and $0.00 in 2024. No product sales exist.
• PIPE-791 (wholly-owned) — Lead asset targeting LPA1R, in a Phase 2 IPF trial (PROPEL-IPF) and previously tested in a Phase 1b chronic pain trial. Contineum retains worldwide rights, so any future value depends on clinical success and approval.
• PIPE-307 / JNJ-5120 (partnered with J&J) — M1R inhibitor licensed exclusively worldwide to J&J. J&J controls development decisions and completed enrollment of 107 patients in the Phase 2 MOONLIGHT-1 MDD trial in June 2026; Contineum's Phase 2 VISTA trial in RRMS did not meet efficacy endpoints.
• Discovery portfolio — Preclinical NI&I programs that the company has streamlined and deprioritized, including deferral of CTX-343 and the PIPE-791 progressive multiple sclerosis program until funding is obtained.

Recent performance

For the second quarter of 2026, Contineum reported a net loss of $15.2 million, compared with $16.0 million in the second quarter of 2025. R&D expenses were $12.7 million, down 10% year over year, while G&A expenses were $4.7 million, up 23%. On April 30, 2026, the company reported positive topline data from its Phase 1b trial of PIPE-791 in chronic osteoarthritis pain or chronic low back pain, which met its safety objective and showed numerically greater pain improvements than placebo. Cash, cash equivalents and marketable securities were $236.6 million as of June 30, 2026. Annual net losses were $42.3 million in 2024 and $60.0 million in 2025, with operating cash flow of negative $55.3 million in 2025.

Strategy

Contineum is concentrating resources on its global Phase 2 PROPEL-IPF trial of PIPE-791, which has more than 55 sites online in eight countries. The company initiated patient dosing in PROPEL-IPF in the first quarter of 2026; it is a 26-week, randomized, double-blind, placebo-controlled trial in approximately 324 IPF patients with a primary endpoint of change from baseline through week 26 in absolute forced vital capacity. Management is also supporting J&J's Phase 2 MOONLIGHT-1 trial of PIPE-307/JNJ-5120 in MDD, which completed enrollment of 107 adults in June 2026. It has streamlined discovery programs toward inflammatory and fibrotic diseases, resulting in a limited workforce reduction including the departure of Chief Scientific Officer Daniel Lorrain, and aims to maintain a disciplined approach to capital allocation.

Risks

• Dependence on two early-stage candidates — The company has no approved products and its business depends heavily on PIPE-791 and PIPE-307, both still in early clinical development.
• Clinical failure risk — The Phase 2 VISTA trial of PIPE-307 in relapsing-remitting multiple sclerosis did not meet its prespecified primary and secondary efficacy endpoints, showing trial outcomes are uncertain.
• Partner control over PIPE-307 — J&J has sole discretion whether to further develop PIPE-307 for RRMS, MDD or any other indication.
• Cash burn and financing need — The company has reported annual net losses, including $60.0 million in 2025, and negative operating cash flow of $55.3 million in 2025, and has deferred certain programs until funding is obtained.

Outlook

Management says its cash resources are sufficient to fund planned operations through mid-2029, which it states is approximately one year past the estimated completion of the IPF trial. The company has affirmed key clinical development milestones and expects to report top-line data from the PIPE-791 chronic pain Phase 1b trial, which it previously guided to the second quarter of 2026. J&J's Phase 2 MOONLIGHT-1 trial of PIPE-307/JNJ-5120 in MDD has completed enrollment. No revenue guidance or product approval timeline is provided.